Alps ETF Trust. Holdings as of May 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Alkermes Plc | 4.48% | $7.24M | 171,723 |
| Kymera Therapeutics IncKYMR | 4.23% | $6.85M | 84,154 |
| Celcuity IncCELC | 3.92% | $6.34M | 47,693 |
| Mirum Pharmaceuticals IncMIRM | 3.90% | $6.31M | 62,199 |
| Spyre Therapeutics IncSYRE | 3.68% | $5.95M | 80,958 |
| Cg Oncology IncCGON | 3.35% | $5.42M | 87,032 |
| Apogee Therapeutics Inc | 2.93% | $4.74M | 57,722 |
| Xenon Pharmaceuticals IncXENE | 2.90% | $4.69M | 85,746 |
| Travere Therapeutics IncTVTX | 2.77% | $4.48M | 95,051 |
| Dianthus Therapeutics IncDNTH | 2.64% | $4.26M | 45,839 |
| Newamsterdam Pharma Co Nv | 2.47% | $3.99M | 118,514 |
| Viking Therapeutics IncVKTX | 2.41% | $3.90M | 119,108 |
| Crinetics Pharmaceuticals Inc | 2.37% | $3.84M | 107,892 |
| Acadia Pharmaceuticals IncACAD | 2.35% | $3.81M | 175,740 |
| Edgewise Therapeutics IncEWTX | 2.33% | $3.78M | 110,576 |
| Denali Therapeutics IncDNLI | 2.13% | $3.44M | 163,467 |
| Oruka Therapeutics IncORKA | 1.81% | $2.92M | 49,896 |
| Structure Therapeutics IncGPCR | 1.78% | $2.87M | 73,020 |
| Disc Medicine IncIRON | 1.69% | $2.74M | 39,334 |
| Ideaya Biosciences IncIDYA | 1.65% | $2.67M | 90,520 |
| Vera Therapeutics IncVERA | 1.61% | $2.61M | 73,552 |
| Tarsus Pharmaceuticals IncTARS | 1.61% | $2.61M | 43,870 |
| Relay Therapeutics IncRLAY | 1.60% | $2.59M | 184,224 |
| Mineralys Therapeutics IncMLYS | 1.59% | $2.57M | 81,578 |
| Celldex Therapeutics IncCLDX | 1.33% | $2.16M | 68,615 |
| Zai Lab LtdZLAB | 1.26% | $2.03M | 115,031 |
| Pharvaris Nv | 1.23% | $1.99M | 66,026 |
| Sionna Therapeutics IncSION | 1.23% | $1.99M | 46,379 |
| Rapport Therapeutics IncRAPP | 1.20% | $1.95M | 49,264 |
| Sarepta Therapeutics IncSRPT | 1.20% | $1.93M | 108,222 |
| Lakefront Biotherapeutics NvLKFT | 1.19% | $1.93M | 67,945 |
| Tyra Biosciences IncTYRA | 1.15% | $1.85M | 55,509 |
| Novavax IncNVAX | 1.14% | $1.84M | 167,949 |
| Stoke Therapeutics IncSTOK | 1.12% | $1.82M | 58,873 |
| Agios Pharmaceuticals IncAGIO | 1.10% | $1.78M | 60,392 |
| Vericel CorpVCEL | 1.08% | $1.74M | 52,309 |
| Nuvation Bio IncNUVB | 1.06% | $1.71M | 357,260 |
| Palvella Therapeutics IncPVLA | 1.03% | $1.67M | 14,096 |
| Taysha Gene Therapies IncTSHA | 1.02% | $1.66M | 282,348 |
| Amylyx Pharmaceuticals IncAMLX | 1.01% | $1.63M | 113,933 |
| Immatics Nv | 0.98% | $1.59M | 138,190 |
| Immunocore Holdings PlcIMCR | 0.93% | $1.51M | 52,254 |
| Mbx Biosciences IncMBX | 0.90% | $1.46M | 46,286 |
| Bicara Therapeutics IncBCAX | 0.88% | $1.42M | 65,313 |
| Moonlake ImmunotherapeuticsMLTX | 0.88% | $1.42M | 73,934 |
| Kalvista Pharmaceuticals Inc | 0.87% | $1.40M | 52,105 |
| Arrivent Biopharma IncAVBP | 0.85% | $1.38M | 45,563 |
| Oculis Holding Ag | 0.84% | $1.35M | 58,929 |
| Maze Therapeutics IncMAZE | 0.81% | $1.31M | 49,602 |
| Mannkind CorpMNKD | 0.74% | $1.20M | 317,578 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.